![](/documents/2560328/2560677/5.1-thank-you-hero-interior_Mobile.png/6978440d-3b79-45af-a71a-5cef6ab8df18?t=1547653117399)
![](/documents/2560328/2560677/5.1-thank-you-hero-interior_Desktop.png/42abc3f2-3a82-4716-80e6-640d50789003?t=1547653116187)
Thank You
Thank you for signing up. You may receive more information about alpha-1, PROLASTIN-C® LIQUID, and the PROLASTIN DIRECT® program in the near future.
![PROLASTIN-C LIQUID alpha-1 Thank You patient quote image](/documents/2560328/2560677/5.1-prolastin-c-liquid-patient-quote_Mobile.png/700486fe-b32e-4eca-a59f-95a6e4c36f58?t=1528300198971)
![PROLASTIN-C LIQUID alpha-1 Thank You patient quote image](/documents/2560328/2560677/5.1-prolastin-c-liquid-patient-quote_Desktop.png/97bf71b1-d08f-49b3-bfe6-691d7baa4964?t=1528298264739)
![PROLASTIN-C Liquid trusted by patients with alpha-1 and their doctors icon](/documents/2560328/2560662/prolastin-c-liquid-trusted-patients-alpha-1-doctors_Desktop.png/72e41559-5b2a-4e20-adb2-147802149b04?t=1715611982742)
PROLASTIN-C LIQUID: The trusted leader for more than 30 years
PROLASTIN-C LIQUID is the #1 prescribed augmentation therapy, trusted by patients with alpha-1 and their doctors for more than 30 years. More than 4 million PROLASTIN-C infusions have been performed around the world.1
IMPORTANT SAFETY INFORMATION
PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Limitations of Use
- The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.
Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).
Please see full Prescribing Information for PROLASTIN-C LIQUID.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
Reference: 1. Data on file, Grifols.